Creative Biomart Blog

Tue, 2025/05/13

Synthetic lethality Synthetic lethality is not a new concept. It refers to the phenomenon where the simultaneous inhibition of two non-lethal genes leads to cell death. This holds extraordinary significance in cancer treatment, as this mechanism can be leveraged to develop drugs that specifically kill cancer cells without affecting normal cells. This has sparked a global rush among researchers to develop synthetic lethality targets. Synthetic lethality Targets Currently, among synthetic lethality targets, only PARP inhibitors have multiple products approved and marketed, including blockbusters

Sun, 2025/04/13

The common types of linkers in ADC drugs and their cleavage mechanisms in vivo

ADC drugs refer to monoclonal antibodies linked to cytotoxic small molecule payloads through covalent linkers to achieve targeted drug delivery. As of now, more than 11 ADC drugs have been approved for the market. Mechanism of Targeted Therapy in ADC Drugs Traditional Mechanism The antibody binds to antigens on the surface of target cells. It enters the lysosome through endocytosis, where enzymes or acids degrade the ADC, releasing the payload. The cytotoxic payload kills the tumor cells, achieving high selectivity in anti-tumor effects. In some cases, the payload has strong permeability, all

Sun, 2025/04/13

PD-(L)1 Antibodies in Small Cell Lung Cancer (SCLC)

Nivolumab and pembrolizumab, known as the "OK duo" of immune checkpoint inhibitors, have both failed in clinical trials for small cell lung cancer (SCLC), leading to the withdrawal of their FDA accelerated approvals for this indication. Subsequent PD-L1 inhibitors, such as atezolizumab and durvalumab, achieved breakthroughs in overall survival (OS) and were approved by the FDA. In the face of robust evidence from clinical trials, a widespread, albeit informal, consensus has emerged in the medical community: PD-1 inhibitors may improve progression-free survival (PFS) in SCLC but fail to transla

Sun, 2025/04/13

Why is it said that middle-aged people find everything difficult except for gaining weight

Why is it said that “middle-aged people find everything difficult except for gaining weight”? Research has found the culprit: a significant reduction in key anti-inflammatory molecules in the EVs secreted by middle-aged people’s fat cells, leading to metabolic disorders. This study is the first to uncover why middle-aged people are more prone to obesity: as the adipose progenitor cells age, the extracellular vesicles (EVs) they secrete can no longer effectively convey anti-inflammatory signals (miR-145-5p), resulting in uncontrolled macrophages that cause adipose tissue infla

Sun, 2025/04/13

Nat Aging: A New Epigenetic Clock Reshapes the Way People Predict Biological Age

A team at Brigham and Women’s Hospital in the USA developed a new “clock” that may help uncover what contributes to aging. They’ve introduced a novel form of epigenetic clock, a machine learning model created to predict biological age from DNA structure. This new model differentiates between genes that retard aging and those accelerating it, accurately predicting biological age and assessing the efficacy of anti-aging interventions. Their findings were published online in Nature Aging, in a paper titled “Causality-enriched epigenetic age uncouples damage and adapt

Fri, 2025/03/14

Scientists Discover Key Mechanism by Which A Β Promotes Tau Protein Diffusion

Recently, Nicolai Franzmeier's team from the Stroke and Dementia Research Institute at the University of Munich in Germany published an important research result. They found that the overactivity and enhanced functional connectivity of neurons induced by Aβ pathology are key factors in promoting the spread of tau pathology. Specifically, the study first found that Aβ deposition enhances the functional connectivity between the pathological initiation core area of tau (lower temporal lobe) and the pathological susceptibility brain areas of tau (such as parietal and occipital lobes). Su

Fri, 2025/03/14

New research paves the way for immunotherapy for childhood cancer

In a new study, researchers from Karolinska Institute and Astrid Lindgren Children's Hospital have determined how children's immune systems respond to different types of cancer based on age. This discovery reveals significant differences in immune responses between children and adults, and may provide new tailored treatment options for children with cancer. The relevant research results were published online in the Cell journal, with the paper titled “Systems-level immunomonitoring in children with solid tumors to enable precision medicine”. “The activation of the immune syst

Fri, 2025/03/14

Discovery of short IL-18 and revelation of its anti-tumor mechanism

Meng Guangxun's team from the Chinese Academy of Sciences Shanghai Institute of Immunology and Infection cooperated with Liu Chenying's team from the Xinhua Hospital affiliated to the School of Medicine of Shanghai Jiaotong University, and published a research paper entitled “Short IL-18 generated by caspase-3 cleavage mobilizes NK cells to suppress tumor growth” in the journal Nature Immunology. This study found that short IL-18 produced by caspase-3 cleavage exerts inhibitory effects on tumor growth by mobilizing NK cells. Our Related Products In this new study, the research tea